Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49677

1.

PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks.

Cutumisu M, Vasquez C, Uhlich M, Beatty PH, Hamayeli-Mehrabani H, Djebah R, Murtha A, Greiner R, Lewis JD.

JCO Clin Cancer Inform. 2019 May;(3):1-12. doi: 10.1200/CCI.18.00144.

2.

Apparent diffusion coefficient in extraprostatic extension of prostate cancer: a systematic review and diagnostic meta-analysis.

Bai K, Sun Y, Li W, Zhang L.

Cancer Manag Res. 2019 Apr 11;11:3125-3137. doi: 10.2147/CMAR.S191738. eCollection 2019.

3.

Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists.

Kappen S, Jürgens V, Freitag MH, Winter A.

Cancer Manag Res. 2019 Apr 16;11:3079-3097. doi: 10.2147/CMAR.S193325. eCollection 2019.

4.

Chromogranin A is a predictor of prognosis in patients with prostate cancer: a systematic review and meta-analysis.

Guo Z, Wang Y, Xiang S, Wang S, Chan FL.

Cancer Manag Res. 2019 Apr 5;11:2747-2758. doi: 10.2147/CMAR.S190678. eCollection 2019.

5.

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer.

Bretoni A, Ferrario L, Foglia E.

Clinicoecon Outcomes Res. 2019 Apr 17;11:283-300. doi: 10.2147/CEOR.S189436. eCollection 2019.

6.

Leptin rs7799039 (G2548A) polymorphism is associated with cancer risk: a meta-analysis involving 25,799 subjects.

Tang W, Kang M, Liu C, Qiu H.

Onco Targets Ther. 2019 Apr 16;12:2879-2890. doi: 10.2147/OTT.S190093. eCollection 2019.

7.

Methyl-β-cyclodextrin, an actin depolymerizer augments the antiproliferative potential of microtubule-targeting agents.

Mundhara N, Majumder A, Panda D.

Sci Rep. 2019 May 21;9(1):7638. doi: 10.1038/s41598-019-43947-4.

8.

Barriers to obtaining prostate multi-parametric magnetic resonance imaging in African-American men on active surveillance for prostate cancer.

Walton EL, Deebajah M, Keeley J, Fakhouri S, Yaguchi G, Pantelic M, Rogers C, Park H, Menon M, Peabody JO, Dabaja A, Alanee S.

Cancer Med. 2019 May 21. doi: 10.1002/cam4.2149. [Epub ahead of print]

9.

MiR-455-5p Suppresses the Progression of Prostate Cancer by Targeting CCR5.

Xing Q, Xie H, Zhu B, Sun Z, Huang Y.

Biomed Res Int. 2019 Apr 11;2019:6394784. doi: 10.1155/2019/6394784. eCollection 2019.

10.

Does early depressive mood expire following radical retropubic prostatectomy in patients with localized prostate cancer?

Chung KJ, Shim SR, Brown S, Shim YS, Park IB, Kim KH.

J Exerc Rehabil. 2019 Apr 26;15(2):264-269. doi: 10.12965/jer.1938160.080. eCollection 2019 Apr.

11.

Long-Term Clinical Outcomes of Radical Prostatectomy versus Watchful Waiting in Localized Prostate Cancer Patients: A Systematic Review and Meta-Analysis.

Nouhi M, Mousavi SM, Olyaeemanesh A, Shaksisalim N, Akbari Sari A.

Iran J Public Health. 2019 Apr;48(4):566-578. Review.

12.

Role of pannexin-1 in the cellular uptake, release and hydrolysis of anandamide by T84 colon cancer cells.

Alhouayek M, Sorti R, Gilthorpe JD, Fowler CJ.

Sci Rep. 2019 May 20;9(1):7622. doi: 10.1038/s41598-019-44057-x.

13.

Epigenetic Control of Gene Expression in the Normal and Malignant Human Prostate: A Rapid Response Which Promotes Therapeutic Resistance.

Frame FM, Maitland NJ.

Int J Mol Sci. 2019 May 17;20(10). pii: E2437. doi: 10.3390/ijms20102437. Review.

14.

Patterns and predictors of self-reported clinical diagnosis and treatment for depression in prostate cancer survivors.

Erim DO, Bensen JT, Mohler JL, Fontham ETH, Song L, Farnan L, Delacroix SE, Peters ES, Erim TN, Chen RC, Gaynes BN.

Cancer Med. 2019 May 20. doi: 10.1002/cam4.2239. [Epub ahead of print]

15.

Editorial: Emerging Biomarkers in Genitourinary Tumors.

Montironi R, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L.

Front Oncol. 2019 Apr 26;9:326. doi: 10.3389/fonc.2019.00326. eCollection 2019. No abstract available.

16.

The human positive cofactor 4 promotes androgen-independent prostate cancer development and progression through HIF-1α/β-catenin pathway.

Luo P, Jiang Q, Fang Q, Wang Y, Wang Z, Yang J, Tan X, Li W, Shi C.

Am J Cancer Res. 2019 Apr 1;9(4):682-698. eCollection 2019.

17.

Prostate cancer cell growth characteristics in serum and prostate-conditioned media from moderate-intensity exercise-trained healthy and tumor-bearing rats.

Opoku-Acheampong AB, Baumfalk DR, Horn AG, Kunkel ON, Ganta CK, McCullough DJ, Siemann DW, Muller-Delp J, Behnke BJ.

Am J Cancer Res. 2019 Apr 1;9(4):650-667. eCollection 2019.

18.
19.

Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort Study.

Lengwiler E, Stampf S, Zippelius A, Salati E, Zaman K, Schäfer N, Schardt J, Siano M, Hofbauer G, The Swiss Transplant Cohort Study.

Swiss Med Wkly. 2019 May 19;149:w20078. doi: 10.4414/smw.2019.20078. eCollection 2019 May 6.

20.

Novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, AZD2461, down-regulates VEGF and induces apoptosis in prostate cancer cells

Sargazi S, Saravani R, Zavar Reza J, Zarei Jaliani H, Galavi H, Moudi M, Abtahi NA.

Iran Biomed J. 2019 May 18. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center